{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:41:42Z","timestamp":1780605702686,"version":"3.54.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,16]]},"DOI":"10.7759\/cureus.88101","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T18:14:00Z","timestamp":1752689640000},"source":"Crossref","is-referenced-by-count":1,"title":["Immune Checkpoint Inhibitor-Induced Myositis, Myocarditis, and Myasthenia Gravis Overlap Syndrome Following Nivolumab and Ipilimumab Combination Therapy in a 60-Year-Old Male With Metastatic Renal Cell Carcinoma"],"prefix":"10.7759","author":[{"given":"Umar","family":"Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124427","article-title":"Combination of ipilimumab and nivolumab in cancers: from clinical practice to ongoing clinical trials","volume":"21","author":"Kooshkaki O","year":"2020","unstructured":"Kooshkaki O, Derakhshani A, Hosseinkhani N, et al.. Combination of ipilimumab and nivolumab in cancers: from clinical practice to ongoing clinical trials. Int J Mol Sci. 2020, 21:4427. 10.3390\/ijms21124427","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak R","year":"2021","unstructured":"Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R. Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist. 2021, 26:1052-61. 10.1002\/onco.13931","journal-title":"Oncologist"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen J","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al.. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022, 33:1217-38. 10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2022.2108827","article-title":"Adverse events induced by nivolumab plus ipilimumab vs. nivolumab monotherapy among cancer patients: a systematic review and meta-analysis","volume":"40","author":"Kamat S","year":"2022","unstructured":"Kamat S, Patel J, Brown BR, Vyas A. Adverse events induced by nivolumab plus ipilimumab vs. nivolumab monotherapy among cancer patients: a systematic review and meta-analysis. Cancer Invest. 2022, 40:777-88. 10.1080\/07357907.2022.2108827","journal-title":"Cancer Invest"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson DB","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al.. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016, 375:1749-55. 10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.84121","article-title":"Rapid-onset myositis and myocarditis following dual immune checkpoint inhibitor therapy with nivolumab and ipilimumab for gastric adenocarcinoma: a case report","volume":"17","author":"Barker SB","year":"2025","unstructured":"Barker SB, Adewuyi A. Rapid-onset myositis and myocarditis following dual immune checkpoint inhibitor therapy with nivolumab and ipilimumab for gastric adenocarcinoma: a case report. Cureus. 2025, 17:e84121. 10.7759\/cureus.84121","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14161794","article-title":"Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review","volume":"14","author":"Lipe DN","year":"2024","unstructured":"Lipe DN, Qdaisat A, Krishnamani PP, et al.. Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review. Diagnostics (Basel). 2024, 14:1794. 10.3390\/diagnostics14161794","journal-title":"Diagnostics (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/383174-immune-checkpoint-inhibitor-induced-myositis-myocarditis-and-myasthenia-gravis-overlap-syndrome-following-nivolumab-and-ipilimumab-combination-therapy-in-a-60-year-old-male-with-metastatic-renal-cell-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T18:14:01Z","timestamp":1752689641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/383174-immune-checkpoint-inhibitor-induced-myositis-myocarditis-and-myasthenia-gravis-overlap-syndrome-following-nivolumab-and-ipilimumab-combination-therapy-in-a-60-year-old-male-with-metastatic-renal-cell-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.88101","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,16]]}}}